Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension.

Abstract

PURPOSE:

The aim of this study was to evaluate the efficacy and safety of brimonidine 0.2% versus brimonidine Purite 0.15% in Asians with ocular hypertension.

METHODS:

This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2% or brimonidine Purite 0.15%, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks.

RESULTS:

The baseline intraocular pressure (IOP) was 24.4 +/- 2.45 mmHg for brimonidine 0.2% and 24.39 +/- 2.56 mmHg for brimonidine Purite 0.15% (P = 0.985). The IOP was at trough drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% therapy were 20.10 +/- 2.01 mmHg and 21.00 +/- 1.67 mmHg (P = 0.001), respectively. The IOP at peak drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% treatment were 18.10 +/- 1.73 mmHg and 18.20 +/- 1.71 mmHg (P = 0.518), respectively. Brimonidine 0.2% was found to cause more allergic conjunctivitis than brimonidine Purite 0.15% (P < 0.001).

CONCLUSIONS:

Brimonidine 0.2% has a higher potency of lowering IOP than brimonidine Purite 0.15% at trough when used twice-daily. However, ocular allergic reaction was more frequent and severe with brimonidine 0.2% than with brimonidine Purite 0.15%.

• Authors: Chan Yun Kim, Samin Hong, Gong Je Seong
• Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (J Ocul Pharmacol Ther) Vol. 23 Issue 5 Pg. 481-6 (Oct 2007) ISSN: 1080-7683 [Print] United States
• PMID: 17900227 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-Agonists
• Antihypertensive Agents
• Ophthalmic Solutions
• Preservatives, Pharmaceutical
• Quinoxalines
• Brimonidine Tartrate

Topics

• Administration, Topical
• Adrenergic alpha-Agonists (administration & dosage, adverse effects, therapeutic use)
• Adult
• Antihypertensive Agents (administration & dosage, adverse effects, therapeutic use)
• Asia
• Asian People
• Brimonidine Tartrate
• Conjunctivitis, Allergic (chemically induced)
• Cross-Over Studies
• Female
• Humans
• Intraocular Pressure (drug effects)
• Male
• Ocular Hypertension (drug therapy)
• Ophthalmic Solutions
• Pigment Epithelium of Eye (metabolism)
• Preservatives, Pharmaceutical
• Prospective Studies
• Quinoxalines (administration & dosage, adverse effects, therapeutic use)
• Single-Blind Method
• Therapeutic Equivalency